000538 云南白药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入41,186,9992.88%39,111,29236,488,37336,373,91932,742,767
减:营业总成本36,210,2242.85%35,082,75032,087,16831,739,81828,425,125
    其中:营业成本29,032,9230.58%28,744,51826,883,48526,498,43523,655,878
               财务费用(46,890)-69.86%(259,244)(342,878)(258,281)(231,946)
               资产减值损失(258,372)183.21%(58,128)(664,339)(143,220)(125,480)
公允价值变动收益110,489-19.25%123,566(619,903)(1,929,217)2,240,369
投资收益1,042,98634.24%779,011868,1981,044,401392,173
    其中:对联营企业和合营企业的投资收益989,14227.75%628,532732,233(21,100)6,308
营业利润6,038,8955.73%4,830,5063,371,2793,485,1696,812,003
利润总额6,043,2716.31%4,818,0123,377,0023,481,6466,801,136
减:所得税费用853,330-7.01%695,451536,593683,9861,290,099
净利润5,189,9418.87%4,122,5612,840,4102,797,6615,511,036
减:非控股权益36,454106.46%28,779(160,716)(7,256)(5,036)
股东净利润5,153,4878.51%4,093,7823,001,1262,804,9175,516,072

市场价值指针
每股收益 (元) *2.8908.65%2.2901.9002.2104.320
每股派息 (元) *2.6028.51%2.0771.5201.6003.900
每股净资产 (元) *22.4433.12%22.19421.42829.80029.789
审计意见 #标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容